Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2018
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary) ; Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 11 Jul 2017 Status changed from recruiting to completed.
- 14 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
- 14 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.